Presentations highlight leadership in RNA splicing, a strategic focus area of the H3 cancer genomics product engine
Cambridge, Mass., April 10, 2018 — H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of next-generation cancer medicines using its data science and precision chemistry product engine, announced today two presentations at the upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting, being held April 14–18, 2018 in Chicago. Both presentations underscore the Company’s scientific leadership in RNA splicing, including the identification of somatic mutations in cancer for the discovery and development of novel therapies.
Oral Presentation / Education Session – Saturday, April 14; 2:00 – 2:25 p.m. (CDT)
Discovery of H3B-8800: A novel, orally bioavailable, small molecule SF3b modulator
Location: Room S103 – McCormick Place South (Level 1)
Presenter: Dominic Reynolds, Ph.D., Vice President of Chemistry, H3 Biomedicine Inc.
Poster Presentation – Tuesday, April 17; 8:00 a.m. to 12:00 p.m. (CDT)
Comprehensive genomic profiling of hematologic malignancies identifies recurrent somatic splicing factor mutations in non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM)
Abstract 3406, Location: Main Exhibit Hall, Section 17, Poster Board 18
This poster presentation is related to a multi-year, ongoing collaboration between H3 Biomedicine and Foundation Medicine, Inc. (NASDAQ:FMI) for the discovery and development of precision medicines in oncology.
Splicing modulation is one of several research focus areas of H3 Biomedicine. A Phase 1 trial is underway in patients with hematologic malignancies for H3B-8800, the company’s first spliceosome pathway-targeting cancer therapeutic. H3B-8800 is a potent, selective and orally bioavailable small molecule modulator of wild-type and mutant SF3b complex, a splicing factor gene. The study is evaluating the safety and preliminary efficacy of H3B-8800 in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML) who carry mutations in splicing factor genes. In February 2018, H3 published preclinical data in Nature Medicine demonstrating that H3B-8800 modulates RNA splicing and shows preferential antitumor activity in a range of spliceosome-mutant cancer models.
About H3 Biomedicine Inc.
H3 Biomedicine, a Cambridge, Massachusetts-based biopharmaceutical company specializing in the discovery and development of precision oncology treatments, was established in 2011 as a subsidiary of Eisai’s U.S. pharmaceutical operation, Eisai Inc. H3 Biomedicine combines long-term vision with operational excellence, leveraging its collaboration with Eisai Co., Ltd., who provides essential research funding and access to the capabilities and resources of a global pharmaceutical company. Using modern synthetic chemistry, chemical biology and human genetics, H3 Biomedicine seeks to bring the next generation of genomics-based cancer treatments to market with the goal of improving the lives of patients. For more information, please visit www.h3biomedicine.com.